Abstract
Tuberculosis (TB), an ongoing public health threat, is worsened by the emergence of drug resistance. With an estimated 630000 cases per year of multidrug resistant (MDR)-TB, and 9% of those being extensively drug resistant (XDR)-TB, there is an urgent need for new and more effective anti-TB drugs. New TB treatment regimens should be able to shorten the duration of therapy that currently takes at least six months. The non-compliance with this long treatment duration is one of the reasons for the development of drug resistance. In spite of the difficulties and alleged lack of interest from the pharmaceutical industry for the discovery and development of new antibiotics, several new or repurposed drugs are being evaluated in clinical trials. This review article summarizes the information available and presents an update on the drugs currently in clinical trials for TB and briefly introduces some new compounds in pre-clinical development.
Keywords: Antibiotics, clinical trials, drug development, drug resistance, tuberculosis.
Current Medicinal Chemistry
Title:Tuberculosis Clinical Trial Update and the Current Anti-Tuberculosis Drug Portfolio
Volume: 20 Issue: 30
Author(s): Juan Carlos Palomino and Anandi Martin
Affiliation:
Keywords: Antibiotics, clinical trials, drug development, drug resistance, tuberculosis.
Abstract: Tuberculosis (TB), an ongoing public health threat, is worsened by the emergence of drug resistance. With an estimated 630000 cases per year of multidrug resistant (MDR)-TB, and 9% of those being extensively drug resistant (XDR)-TB, there is an urgent need for new and more effective anti-TB drugs. New TB treatment regimens should be able to shorten the duration of therapy that currently takes at least six months. The non-compliance with this long treatment duration is one of the reasons for the development of drug resistance. In spite of the difficulties and alleged lack of interest from the pharmaceutical industry for the discovery and development of new antibiotics, several new or repurposed drugs are being evaluated in clinical trials. This review article summarizes the information available and presents an update on the drugs currently in clinical trials for TB and briefly introduces some new compounds in pre-clinical development.
Export Options
About this article
Cite this article as:
Palomino Carlos Juan and Martin Anandi, Tuberculosis Clinical Trial Update and the Current Anti-Tuberculosis Drug Portfolio, Current Medicinal Chemistry 2013; 20 (30) . https://dx.doi.org/10.2174/09298673113209990166
DOI https://dx.doi.org/10.2174/09298673113209990166 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Determination of Human Serum α1-Acid Glycoprotein and Albumin Binding of Various Marketed and Preclinical Kinase Inhibitors
Current Medicinal Chemistry On the Paradigm Shift Towards Multitarget Selective Drug Design
Current Computer-Aided Drug Design Increased [11C]Choline Uptake in Bronchioloalveolar Cell Carcinoma with Negative [18F]FDG Uptake. A PET/CT and Pathology Study
Current Radiopharmaceuticals Treatment Outcomes of the Standardized Shorter MDR-TB Regimen Under Programmatic Setting: A Retrospective Study from a Tertiary Care Centre, India
Current Respiratory Medicine Reviews Gene Therapy by Liver Transplantation and Single Stranded Oligonucleotides (SSOs) in Familial Amyloidotic Polyneuropathy (FAP)
Current Pharmacogenomics The Gut Microbiota in Inflammatory Bowel Disease
Current Pharmaceutical Design Isoniazid: Metabolic Aspects and Toxicological Correlates
Current Drug Metabolism Tuberculous Tenosynovitis of the Wrist: A Report of Two Cases with Special Reference to Magnetic Resonance Findings
Current Medical Imaging Fc-Independent Phagocytosis: Implications for Intravenous IgG Therapy in Immune Thrombocytopenia
Cardiovascular & Hematological Disorders-Drug Targets Synthesis of Gold Mediated Biocompatible Nanocomposite of Lactone Enriched Fraction from Sahadevi (Vernonia cinerea Lees): An Assessment of Antimalarial Potential
Current Topics in Medicinal Chemistry Bioactive Carbohydrates and Recently Discovered Analogues as Chemotherapeutics
Mini-Reviews in Medicinal Chemistry MIF and the Genetic Basis of Macrophage Responsiveness
Current Immunology Reviews (Discontinued) Synthesis and Anti-onchocercal Activity of Isonicotinoylhydrazones and their Copper(II) and Zinc(II) Complexes
Anti-Infective Agents Thalidomide: A Banned Drug Resurged into Future Anticancer Drug
Current Drug Therapy Personalized Medicine, Bioethics and Social Responsibilities: Re-thinking the Pharmaceutical Industry to Remedy Inequities in Patient Care and International Health
Current Pharmacogenomics and Personalized Medicine Fight Against H1N1 Influenza A Virus: Recent Insights Towards the Development of Druggable Compounds
Current Medicinal Chemistry Editorial (Thematic Issue: Searching a New Antibiotic Prototype: Snake Venoms)
Mini-Reviews in Organic Chemistry HIV Vaccines: A Global Perspective
Current Molecular Medicine Extrapulmonary Sarcoidosis: A Chameleon Disease at Imaging
Current Medical Imaging Non-Covalent Proteasome Inhibitors
Current Pharmaceutical Design